Erratum: Influence of cocaine history on the behavioral effects of dopamine d3 receptor-selective compounds in monkeys (Neuropsychopharmacology (2011) 36 (1104-1113) DOI: 10.1038/npp.2010.248);Influence of cocaine history on the behavioral effects of dopamine D 3 receptor-selective compounds in monkeys

Neuropsychopharmacology

Volumn 36, Issue 5, 2011, Pages 1104-1113

  Blaylock, B L ^a   Gould, R W ^a   Banala, A ^b   Grundt, P ^b   Luedtke, R R ^c   Newman, A H ^b   Nader, M A ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^c UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

Author keywords

addiction and substance abuse; cocaine; nonhuman primates; reinstatement; self administration

Indexed keywords

1 PHENYLPIPERAZINE DERIVATIVE; CJB 090; COCAINE; N [3 HYDROXY 4 [4 (2 METHOXYPHENYL)PIPERAZIN 1 YL]BUTYL] 4 (PYRIDIN 2 YL)BENZAMIDE; N [4 [4 (2,3 DICHLOROPHENYL)PIPERAZIN 1 YL]BUTYL] 4 (PYRIDIN 2 YL)BENZAMIDE; N [4 [4 (2,3 DICHLOROPHENYL)PIPERAZIN 1 YL]BUTYL] 9H FLUORENE 2 CARBOXAMIDE; NGB 2904; PG 619; QUINPIROLE; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SEEKING BEHAVIOR; DRUG SELECTIVITY; DRUG SELF ADMINISTRATION; DRUG STRUCTURE; HUMAN; HUMAN CELL; IC 50; MALE; NONHUMAN; PRIORITY JOURNAL; YAWNING;

EID: 79952750843     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2012.98     Document Type: Erratum

References (51)

1. Achat-Mendes C, Grundt P, Cao J, Platt DM, Newman AH, Spealman RD (2010). Dopamine D3 and D2 receptor mechanisms in the abuse-related behavioral effects of cocaine: studies with preferential antagonists in squirrel monkeys. J Pharmacol Exp Ther 334: 556-565.
2. Achat-Mendes C, Platt DM, Newman AH, Spealman RD (2009). The dopamine D3 receptor partial agonist CJB 090 inhibits the discriminative stimulus but not the reinforcing or priming effects of cocaine in squirrel monkeys. Psychopharmacology 206: 73-84.
3. Baladi MG, Newman AH, France CP (2010). Dopamine D3 receptors mediate the discriminative stimulus effects of quinpir-ole in free-feeding rats. J Pharmacol Exp Ther 332: 308-315.
4. Boeckler F, Gmeiner P (2006). The structural evolution of dopamine D3 receptor ligands: structure-activity relationships and selected neuropharmacological aspects. Pharmacol Ther 112: 281-333. (Pubitemid 44301495)
5. Caine SB, Koob GF (1993). Modulation of cocaine self-administration in the rat through D-3 dopamine receptors. Science 260: 1814-1816.
6. Caine SB, Negus SS, Mello NK (2000). Effects of dopamine D1-like and D2-like agonists on cocaine self-administration in rhesus monkeys: rapid assessment of cocaine dose-effect curves. Psychopharmacology 148: 41-51. (Pubitemid 30062471)
7. Carroll FI, Howell LL, Kuhar MJ (1999). Pharmacotherapies for treatment of cocaine abuse: preclinical aspects. J Med Chem 42: 2721-2736. (Pubitemid 29370417)
8. Cervo L, Carnovali F, Stark JA, Mennini T (2003). Cocaine-seeking behavior in response to drug-associated stimuli in rats: involvement of D3 and D2 dopamine receptors. Neuropsycho-pharmacology 28: 1150-1159.
9. Clarke WP (2005). What's for lunch at the conformational cafeteria? Mol Pharmacol 67: 1819-1821. (Pubitemid 41007762)
10. Code RA, Tang AH (1991). Yawning produced by dopamine agonists in rhesus monkeys. Eur J Pharmacol 201: 235-238.
11. 0-propyl-4,5,6,7-tetrahydroben-zothiazole-2,6- diamine dihydrochloride (pramipexole)-induced yawning, hypothermia, and locomotor activity in rats: evidence for sensitization of dopamine D2 receptor-mediated effects. J Pharmacol Exp Ther 325: 691-697. (Pubitemid 351574782)
12. Collins GT, Newman AH, Grundt P, Rice KC, Husbands SM, Chauvignac C et al. (2007). Yawning and hypothermia in rats: effects of dopamine D3 and D2 agonists and antagonists. Psychopharmacology 193: 159-170. (Pubitemid 47025018)
13. Collins GT, Witkin JM, Newman AH, Svensson KA, Grundt P, Cao J et al. (2005). Dopamine agonist-induced yawning in rats: a dopamine D3 receptor-mediated behavior. J Pharmacol Exp Ther 314: 310-319. (Pubitemid 41058268)
14. Collins GT, Woods JH (2007). Drug and reinforcement history as determinants of the response-maintaining effects of quinpirole in the rat. J Pharmacol Exp Ther 323: 599-605. (Pubitemid 350005111)
15. Collins GT, Woods JH (2009). Influence of conditioned reinforcement on the response-maintaining effects of quinpirole in rats. Behav Pharmacol 20: 492-504.
16. Czoty PW, Gage HD, Nader SH, Reboussin BA, Bounds M, Nader MA (2007). PET imaging of dopamine D2 receptor and transporter availability during acquisition of cocaine self-administration in rhesus monkeys. J Addict Med 1: 33-39.
17. Di Chiara G, Imperato A (1988). Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 85: 5274-5278.
18. Gay EA, Urban JD, Nichols DE, Oxford GS, Mailman RB (2004). Functional selectivity of D2 receptor ligands in a Chinese hamster ovary hD2L cell line: evidence for induction of ligand-specific receptor states. Mol Pharmacol 66: 97-105. (Pubitemid 38822091)
19. 3H]quinpirole binding to dopamine D2 and D3 receptors in rat brain. Eur J Pharmacol 211: 189-194.
20. Grundt P, Carlsson EE, Cao J, Bennett CJ, McElveen E, Taylor M et al. (2005). Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3- dichlorophenyl)piperazin-1-yl]butyl} arylcaroxamides as selective probes with high affinity for the dopamine D3 receptor. J Med Chem 48: 839-884.
21. Grundt P, Prevatt KM, Cao J, Taylor M, Floresca CZ, Choi JK et al. (2007). Heterocyclic analogues of N-(4-(4-(2,3 dichlorophenyl)-piperazin-1-yl) butyl)arylcarboxamides with functionalized linking chains as novel dopamine D3 receptor ligands: potential substance abuse therapeutic agents. J Med Chem 50: 4135-4146. (Pubitemid 47301745)
22. Hamilton LR, Czoty PW, Gage HD, Nader MA (2010). Characterization of the dopamine receptor system in adult rhesus monkeys exposed to cocaine throughout gestation. Psychophar-macology 210: 481-488.
23. Heidbreder CA, Newman AH (2010). Current perspectives on selective dopamine D3 receptor antagonists as pharmacother-apeutics for addictions and related disorders. Ann NY Acad Sci 1187: 4-34.
24. Karila L, Gorelick D, Weinstein A, Noble F, Benyamina A, Coscas S et al. (2008). New treatments for cocaine dependence: a focused review. Int J Neuropsychopharmacol. 11: 425-438. (Pubitemid 351482505)
25. Kebabian JW, Caine DB (1979). Multiple receptors for dopamine. Nature 277: 93-96. (Pubitemid 9093798)
26. Kenakin T (2002). Drug efficacy at G protein-coupled receptors. Ann Rev Pharmacol Toxicol 42: 349-379. (Pubitemid 34160530)
27. 3 receptor and drug dependence: effects on reward or beyond? Neuropharmacology 49: 525-541. (Pubitemid 41169976)
28. Levant B, Grigoriadis DE, DeSouza EB (1992). Characterization of [3H]quinpirole binding to D2-like dopamine receptors in rat brain. J Pharmacol Exp Ther 262: 929-935.
29. 3 dopamine receptor: neurobiology and potential clinical relevance. Pharmacol Rev 49: 231-252. (Pubitemid 27414914)
30. Martelle JL, Claytor R, Ross JT, Reboussin BA, Newman AH, Nader MA (2007). Effects of two novel D3-selective compounds, NGB 2904 and CJB 090, on the reinforcing and discriminative stimulus effects of cocaine in rhesus monkeys. J Pharmacol Exp Ther 321: 573-582.
31. Mello NK, Negus SS (1996). Preclinical evaluation of pharma-cotherapies for treatment of cocaine and opiod abuse using drug self-administration procedures. Neuropsychopharmacology 14: 375-424. (Pubitemid 26271172)
32. Missale C, Nash SR, Robinson SW, Jaber M, Caron MG (1998). Dopamine receptors: from structure to function. Physiol Rev 78: 189-225. (Pubitemid 28070979)
33. 2 receptors in rhesus monkeys. Synapse 30: 88-96. (Pubitemid 28361187)
34. Nader MA, Daunais JB, Moore T, Nader SH, Moore RJ, Smith HR et al. (2002). Effects of cocaine self-administration on striatal dopamine systems in rhesus monkeys: initial and chronic exposure. Neuropsychopharmacology 27: 35-46. (Pubitemid 34626741)
35. 3 agonist 7-OH-DPAT in rhesus monkeys is modified by prior cocaine exposure. Psychopharmacology 125: 13-22. (Pubitemid 26156633)
36. Negus SS (2003). Rapid assessment of choice between cocaine and food in rhesus monkeys: effects of environmental manipulations and treatment with d-amphetamine and flupenthixol. Neuro-psychopharmacology 28: 919-931.
37. Neisewander JL, Fuchs RS, Tran-Nguyen LT, Weber SM, Coffey GP, Joyce JN (2004). Increases in dopamine D3 receptor binding in rats receiving a cocaine challenge at various time points after cocaine self-administration: implications for cocaine-seeking behavior. Neuropsychopharmacology 29: 1479-1487. (Pubitemid 38982240)
38. Newman AH, Grundt P, Nader MA (2005). Dopamine D3 receptor partial agonists and antagonists as potential drug abuse therapeutic agents. J Med Chem 48: 3664-3679.
39. 3 receptor agonist. Nature 400: 371-375. (Pubitemid 29344203)
40. Pilon C, Levesque D, Dimitriadou V, Griffon N, Martres MP, Schwartz JC et al. (1994). Functional coupling of the human dopamine D3 receptor in a transfected NG 108-15 neuroblastoma-glioma hybrid cell line. Eur J Pharmacol 268: 129-139.
41. Ritz MC, Lamb RJ, Goldberg SR, Kuhar MJ (1987). Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science 237: 1219-1223. (Pubitemid 17131228)
42. Saloman Y, Londos C, Rodbell M (1974). A highly sensitive adenylate cyclase assay. Anal Biochem 58: 541-548.
43. Self DW, Barnhart WJ, Lehman DA, Nestler EJ (1996). Opposite modulation of cocaine-seeking behavior by D1- and D2-like dopamine receptor agonists. Science 271: 1586-1589. (Pubitemid 26097217)
44. 3) as a target for neuroleptics. Nature 347: 146-151.
45. 3 dopamine receptors in the brain reward circuits of human cocaine fatalities. J Neurosci 16: 6100-6106. (Pubitemid 26313985)
46. Substance Abuse and Mental Health Services Administration SAMHSA Office of Applied Studies (2008). Results from National Survey on Drug Use and Health.
47. Taylor M, Grundt P, Griffin SA, Newman AH, Luedtke RR (2010). Dopamine D3 receptor selective ligands with varying intrinsic efficacies at adenylyl cyclase inhibition and mitogenic signaling pathways. Synapse 64: 251-266.
48. Vocci JF, Acri J, Elkashef A (2005). Medication development for addictive disorders: the state of the science. Am J Psychiatry 162: 1432-1440. (Pubitemid 41105557)
49. Xi ZX, Gardner EL (2008). Hypothesis-driven medication discovery for the treatment of psychostimulant addiction. Curr Drug Abuse Rev 1: 303-327.
50. Xi ZX, Newman AH, Gilbert JG, Pak AC, Peng XQ, Ashby Jr CR et al. (2006). The novel dopamine D3 receptor antagonist NGB 2904 inhibits cocaine's rewarding effects and cocaine-induced reinstatement of drug-seeking behavior in rats. Neuropsychopharmacology 7: 1393-1405.
51. Zhang A, Neumeyer JL, Baldessarini RJ (2007). Recent progress in development of dopamine receptor subtype-selective agents: potential therapeutics for neurological and psychiatric disorders. Chem Rev 107: 274-302. (Pubitemid 46237370)